TEVA, US8816242098

Fourteen brokerages set USD 46.08 target for Teva stock

Published on 10/27/2026 at 15:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva posted USD 4.14 billion revenue in the second quarter of 2026. Teva stock was USD 40.33 on October 27, 2026 at 10:25 a.m. ET, up 0.95 percent on NYSE.

Analyst view and market position

Fourteen brokerages gave Teva a Moderate Buy consensus and an average USD 46.08 target on October 25, 2026.
Teva reported USD 4.14 billion quarterly revenue and USD 0.02 earnings per share on June 30, 2026.
Teva stock was USD 40.33 on the NYSE on October 27, 2026 at 10:25 a.m. ET, up 0.95 percent from USD 39.95.
Third-quarter results are scheduled for November 3, 2026, followed by an R&D day on November 11, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Fourteen brokerages gave Teva Pharmaceutical Industries a Moderate Buy consensus and an average 12-month target of USD 46.08 on October 25, 2026, according to MarketBeat. The target lies 14.26 percent above the current USD 40.33 quote. Teva stock was trading at USD 40.33 on October 27, 2026 at 10:25 a.m. ET on the NYSE, up 0.95 percent from the prior close of USD 39.95.

Revenue reached USD 4.14 billion

Teva's latest quarterly report carried revenue of USD 4.14 billion and earnings per share of USD 0.02, figures cited by MarketBeat on October 25, 2026. The revenue figure gives the analyst target a business backdrop, while the reported earnings figure remains a separate measure from the current share quotation.

Stock sits 4.02 percent below its high

At USD 40.33, Teva was 4.02 percent below its 52-week high of USD 42.02 and well above its 52-week low of USD 19.23 on October 27, 2026. The company had a market capitalization of USD 47.0 billion, while trading volume stood at 1,826,906 shares at 10:25 a.m. ET.

The price position leaves limited distance to the yearly high but does not by itself establish a new record. For investors, the combination of a USD 46.08 average target and the current USD 40.33 quote puts the analyst view above the market level by a measurable 14.26 percent.

Results and R&D dates are set

Teva is scheduled to discuss its third-quarter results on November 3, 2026, according to the event listing on Gettex. The company is also due to host an R&D day on November 11, 2026. These dates give the target and the second-quarter figures two upcoming points for comparison.

Current quote and company profile

Teva Pharmaceutical Industries develops and sells generic medicines, specialty pharmaceuticals, biosimilars and active pharmaceutical ingredients. The company is headquartered in Tel Aviv, Israel, and operates in the healthcare sector.

Teva stock was trading at USD 40.33 on the NYSE on October 27, 2026 at 10:25 a.m. ET, up 0.95 percent from USD 39.95. The next scheduled reporting date is November 3, 2026.